Physician profile
Bryan Drew Blitstein
NPI 1932185626
$21,359.73
in general payments reported to CMS, 2019-2025
30 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 77% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,381 · 2020: $5,562 · 2021: $1,753 · 2022: $955 · 2023: $455 · 2024: $1,840 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708 · Travel and Lodging: $1,001 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.67 |
| Travel and Lodging | $1,001.00 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,265.44 | 2019-2024 | |
| Reprise Biomedical, INC. | $2,323.02 | 2020-2023 | Miro3d Fibers, Miro3d |
| Stryker Corporation | $2,302.28 | 2024-2025 | Chromophare F300, 1788, Operon |
| Medical Device Business Services, INC. | $941.26 | 2019 | |
| Integra Lifesciences Corporation | $625.78 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Davol INC. | $381.04 | 2019-2023 | Phasix Mesh |
| Tela Bio, INC. | $363.04 | 2020-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Ethicon US, LLC | $189.45 | 2019-2020 | |
| Boston Scientific Corporation | $146.43 | 2020-2023 | Spyglass, Varithena Administration Pack |
| Smith+Nephew, INC. | $97.95 | 2024-2025 | Stravix Pl, Oasis |
| Lucid Diagnostics INC. | $96.38 | 2022 | |
| Conmed Corporation | $81.32 | 2019-2021 | |
| Innocoll Pharmaceuticals Limited | $71.30 | 2021-2022 | |
| Medtronic, INC. | $67.17 | 2024 | Venaseal |
| Csl Behring | $61.79 | 2019-2025 | Kcentra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $51.87 | 2024-2025 | |
| Karl Storz Endoscopy-America | $47.42 | 2025 | |
| Olympus America INC. | $35.77 | 2019-2021 | |
| Abbvie INC. | $31.96 | 2024 | |
| Kerecis Limited | $26.02 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Novartis Pharmaceuticals Corporation | $23.73 | 2023 | |
| Mimedx Group, INC. | $20.98 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.03 | 2022 | |
| Biotissue Holdings INC. | $17.68 | 2024 | |
| Braintree Laboratories, INC. | $16.37 | 2023 | Sutab |
| Pharmacosmos Therapeutics INC. | $14.76 | 2022 | |
| Endogastric Solutions, INC | $14.38 | 2024 | Esophyx |
| Cashflow Solutions, LLC | $14.00 | 2024 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Teleflex LLC | $13.11 | 2023 | Deknatel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Blitstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.